Viking Therapeutics (VKTX) Retained Earnings (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Retained Earnings for 12 consecutive years, with -$847.5 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 73.71% to -$847.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$847.5 million through Dec 2025, down 73.71% year-over-year, with the annual reading at -$847.5 million for FY2025, 73.71% down from the prior year.
- Retained Earnings hit -$847.5 million in Q4 2025 for Viking Therapeutics, down from -$689.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$182.2 million in Q1 2021 to a low of -$847.5 million in Q4 2025.
- Historically, Retained Earnings has averaged -$384.6 million across 5 years, with a median of -$342.1 million in 2023.
- Biggest five-year swings in Retained Earnings: decreased 28.06% in 2024 and later crashed 73.71% in 2025.
- Year by year, Retained Earnings stood at -$223.2 million in 2021, then plummeted by 30.86% to -$292.0 million in 2022, then decreased by 29.41% to -$377.9 million in 2023, then dropped by 29.1% to -$487.9 million in 2024, then tumbled by 73.71% to -$847.5 million in 2025.
- Business Quant data shows Retained Earnings for VKTX at -$847.5 million in Q4 2025, -$689.9 million in Q3 2025, and -$599.1 million in Q2 2025.